EVALUATION OF SERUM LEVEL OF CXCL12 AND ITS RELATION TO DISEASE ACTIVITY IN VITILIGO PATIENTS | ||||
ALEXMED ePosters | ||||
Article 1, Volume 6, Issue 2, April 2024, Page 44-45 | ||||
Document Type: Preliminary preprint short reports of original research | ||||
DOI: 10.21608/alexpo.2024.296695.1862 | ||||
![]() | ||||
Authors | ||||
Eisha AbdElmoneim Ismail1; Eman Moahmed Elearyan2; Mona Moustafa Tahoun3; Alaa Ramadan Mohamed Agwa ![]() | ||||
1Dermatology, Venereology and Andrology, Faculty of Medicine, Alexandria University. | ||||
2Department of Dermatology, Venereology and Andrology , Faculty of Medicine, Alexandria University, Egypt. | ||||
3Department of Clinical and Chemical Pathology, Faculty of Medicine University of Alexandria. | ||||
4Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Alexandria University. | ||||
Abstract | ||||
Vitiligo is a pigmentary disorder with an unknown cause that affects the skin and is characterized by well-defined, depigmented macules and patches that develop as a result of the selective loss of melanocytes. Vitiligo can be classified into segmental and nonsegmental which is the most common and unclassifible vitiligo. The pathogenesis of vitiligo is still unclear but it may be due to interplay of theories including genetic, environmental factors, immunological theory, reactive oxygen system theory, and neural theory. Treatment for vitiligo aims to promote repigmentation and cause stability. There are three types of treatment: pharmaceutical, surgical, and physical. CXCL12 is an effective vitiligo predictor. In early vitiligo, it is produced by epidermal melanocytes and is surrounded by CXCR4+ cells.CXCR4 and CXCL12 have been recognized as critical mediators for mobilizing the IFN-producing cells and Langerhans cellsto the site’s proximity to melanocytes, resulting in melanocyte destruction and pigmentation in the skin. AIM: The aim of this work was to evaluate serum level of C-X-C motif chemokine ligand 12 (CXCL12) and its relation to disease activity in vitiligo patients. | ||||
Keywords | ||||
CXCL12; vitiligo; activity | ||||
Supplementary Files
|
||||
Statistics Article View: 95 |
||||